The effects of 5-HT 4 receptor agonist, mosapride citrate, on visceral hypersensitivity in a rat model

Digestive Diseases and Sciences

Volumn 57, Issue 6, 2012, Pages 1517-1524

  Lee, Jae Woong ^a   Sung, Ki Woon ^b   Lee, Oh Young ^c   Lee, Seo Eun ^b   Sohn, Chong Il ^d  

^a Hanil General Hospital   (South Korea)

^b Hanyang University   (South Korea)

^c Hanyang University College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Colorectal distension; Irritable bowel; Mosapride citrate; Visceral hypersensitivity

Indexed keywords

ACETIC ACID; MOSAPRIDE; SEROTONIN 4 AGONIST; ZYMOSAN; BENZAMIDE DERIVATIVE; MORPHOLINE DERIVATIVE;

ABDOMINAL PAIN; ABDOMINAL WALL MUSCULATURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON DILATATION; ELECTROMYOGRAPHY; HYPERSENSITIVITY REACTION; IRRITABLE COLON; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; VISCERAL PAIN; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; GASTROINTESTINAL MOTILITY; HYPERSENSITIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; REFERENCE VALUE; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; BENZAMIDES; DISEASE MODELS, ANIMAL; ELECTROMYOGRAPHY; GASTROINTESTINAL MOTILITY; HYPERSENSITIVITY; INJECTIONS, INTRAPERITONEAL; MALE; MORPHOLINES; PAIN MEASUREMENT; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; SEROTONIN 5-HT4 RECEPTOR AGONISTS; TREATMENT OUTCOME; VISCERAL PAIN;

EID: 84864184418     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2101-z     Document Type: Article

References (39)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45: II43-II47. (Pubitemid 29434812)
2. Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat. Brain Res. 1988;450:153-169.
3. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology. 2002;122:1771-1777. (Pubitemid 34651420)
4. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut. 1973;14:125-132.
5. Sohn CI, Park HJ, Gebhart GF. Adenosine receptor agonists modulate visceral hyperalgesia in the rat. Gut Liver. 2008;2:39-46.
6. Briejer MR, Akkermans LM, Schuurkes JA. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev. 1995;47:631-651. (Pubitemid 26006144)
7. Fink C, Tatar M, Failing K, Hospes R, Kressin M, Klisch K. Serotonin-containing cells in the gastrointestinal tract of newborn foals and adult horses. Anat Histol Embryol. 2006;35:23-27.
8. Costedio MM, Hyman N, Mawe GM. Serotonin and its role in colonic function and in gastrointestinal disorders. Dis Colon Rectum. 2007;50:376-388. (Pubitemid 46394454)
9. Kim HS, Choi EJ, Park H. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil. 2008;20:169-176.
10. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther. 1997;282: 220-227. (Pubitemid 27425544)
11. Kanazawa M, Watanabe S, Tana C, Komuro H, Aoki M, Fukudo S. Effect of 5-HT(4) receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2011;23:754-e332.
12. Seto Y, Yoshida N, Kaneko H. Effects of mosapride citrate, a 5-HT4-receptor agonist, on gastric distension-induced viscero-motor response in conscious rats. J Pharmacol Sci. 2011;116: 47-53.
13. Sohn CI. Experimental animal models for the study of visceral pain. Korean J Gastroenterol. 2001;38:77-82.
14. Talley NJ. Serotoninergic neuroenteric modulators. Lancet. 2001; 358:2061-2068. (Pubitemid 34084835)
15. Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655-1666. (Pubitemid 32912410)
16. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463-468. (Pubitemid 30140843)
17. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther. 2003;17:577-585. (Pubitemid 36384817)
18. Schikowski A, Thewissen M, Mathis C, Ross HG, Enck P. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil. 2002;14:221-227. (Pubitemid 34639449)
19. Briejer MR, Schuurkes JA. 5-HT3 and 5-HT4 receptors and cholinergic and tachykininergic neurotransmission in the guineapig proximal colon. Eur J Pharmacol. 1996;308:173-180. (Pubitemid 26237044)
20. McLean PG, Coupar IM. Stimulation of cyclic AMP formation in the circular smooth muscle of human colon by activation of 5-HT4-like receptors. Br J Pharmacol. 1996;117:238-239. (Pubitemid 26030275)
21. Mine Y, Yoshikawa T, Oku S, Nagai R, Yoshida N, Hosoki K. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J Pharmacol Exp Ther. 1997;283:1000-1008. (Pubitemid 28016469)
22. Yoshida N, Omoya H, Oka M, Furukawa K, Ito T, Karasawa T. AS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties. Arch Int Pharmacodyn Ther. 1989;300:51-67. (Pubitemid 20000046)
23. Sasaki N, Okamura K, Yamada H. Effects of mosapride, a 5-hydroxytryptamine 4 receptor agonist, on electrical activity of the small intestine and cecum in horses. Am J Vet Res. 2005;66: 1321-1323. (Pubitemid 41613983)
24. Yoshida N, Omoya H, Kato S, Ito T. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung. 1993; 43:1078-1083. (Pubitemid 23311886)
25. Lee JW, Park JH, Park DI, et al. Subjects with diarrheapredominant IBS have increased rectal permeability responsive to tryptase. Dig Dis Sci. 2010;55:2922-2928.
26. Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011;106:1290-1298.
27. 2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors. Mol Pharmacol. 1994;46:1120-1128.
28. Callahan MJ. Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol. 2002;35:S58-S67. (Pubitemid 34663339)
29. Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci. 1990;35:477-480. (Pubitemid 20116748)
30. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil. 2003;15:79-86. (Pubitemid 36313138)
31. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009;104:1831-1843; quiz 1844.
32. Le Bars D, Willer JC, De Broucker T. Morphine blocks descending pain inhibitory controls in humans. Pain. 1992;48: 13-20.
33. Chitour D, Dickenson AH, Le Bars D. Pharmacological evidence for the involvement of serotonergic mechanisms in diffuse noxious inhibitory controls (DNIC). Brain Res. 1982;236:329-337. (Pubitemid 12132555)
34. Kraus E, Besson JM, Le Bars D. Behavioral model for diffuse noxious inhibitory controls (DNIC): potentiation by 5-hydroxytryptophan. Brain Res. 1982;231:461-465. (Pubitemid 12203143)
35. Sivarao DV, Langdon S, Bernard C, Lodge N. Colorectal distension-induced pseudoaffective changes as indices of nociception in the anesthetized female rat: morphine and strain effects on visceral sensitivity. J Pharmacol Toxicol Methods. 2007;56: 43-50. (Pubitemid 46839195)
36. Laird JM, Martinez-Caro L, Garcia-Nicas E, Cervero F. A new model of visceral pain and referred hyperalgesia in the mouse. Pain. 2001;92:335-342. (Pubitemid 32480163)
37. Lu G, Qian X, Berezin I, Telford GL, Huizinga JD, Sarna SK. Inflammation modulates in vitro colonic myoelectric and contractile activity and interstitial cells of Cajal. Am J Physiol. 1997;273:G1233-G1245.
38. La JH, Kim TW, Sung TS, Kang JW, Kim HJ, Yang IS. Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis. World J Gastroenterol. 2003;9:2791-2795.
39. Jones RC 3rd, Otsuka E, Wagstrom E, Jensen CS, Price MP, Gebhart GF. Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouse. Gastroenterology. 2007;133:184-194. (Pubitemid 47031128)